These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23673908)

  • 21. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
    Allard P; Gram L; Timdahl K; Behnke K; Hanson M; Søgaard J
    Int J Geriatr Psychiatry; 2004 Dec; 19(12):1123-30. PubMed ID: 15526307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
    Luthringer R; Toussaint M; Schaltenbrand N; Bailey P; Danjou PH; Hackett D; Guichoux JY; Macher JP
    Psychopharmacol Bull; 1996; 32(4):637-46. PubMed ID: 8993085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT
    J Clin Psychiatry; 2013 Oct; 74(10):1010-7. PubMed ID: 24229754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study.
    Lopresti AL; Drummond PD
    J Affect Disord; 2017 Jan; 207():188-196. PubMed ID: 27723543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change.
    Lopresti AL; Maes M; Meddens MJ; Maker GL; Arnoldussen E; Drummond PD
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):38-50. PubMed ID: 25523883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.
    Holtzheimer PE; Meeks TW; Kelley ME; Mufti M; Young R; McWhorter K; Vito N; Chismar R; Quinn S; Dey S; Byrd EH; McDonald WM
    Int J Geriatr Psychiatry; 2008 Jun; 23(6):625-31. PubMed ID: 18058832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
    Warden D; Trivedi MH; Carmody T; Toups M; Zisook S; Lesser I; Myers A; Kurian KR; Morris D; Rush AJ
    J Psychiatr Pract; 2014 Mar; 20(2):118-32. PubMed ID: 24638046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial.
    Sanmukhani J; Satodia V; Trivedi J; Patel T; Tiwari D; Panchal B; Goel A; Tripathi CB
    Phytother Res; 2014 Apr; 28(4):579-85. PubMed ID: 23832433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
    Lopresti AL; Maes M; Maker GL; Hood SD; Drummond PD
    J Affect Disord; 2014; 167():368-75. PubMed ID: 25046624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study.
    Altamura AC; Dell'Osso B; Buoli M; Bosi M; Mundo E
    Int Clin Psychopharmacol; 2008 Jul; 23(4):198-202. PubMed ID: 18545057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial.
    Pope HG; Cohane GH; Kanayama G; Siegel AJ; Hudson JI
    Am J Psychiatry; 2003 Jan; 160(1):105-11. PubMed ID: 12505808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.